What Is Poviztra? Complete Guide

What Is Poviztra?

Poviztra is a prescription medication for chronic weight management in adults, sold in India. It contains semaglutide and is Novo Nordisk's second brand of Wegovy in India, marketed and distributed by Emcure Pharma under a partnership announced in November 2025. Emcure launched it across India on December 22, 2025. It is intended to be used as a component of a comprehensive health plan that also includes a reduced-calorie diet and increased physical activity.

As with Wegovy, its indication also includes reducing the risk of major cardiovascular events in people with overweight or obesity and established heart disease. Poviztra is not sold in the US or UK, where the same medicine is available as Wegovy.

The active ingredient in Poviztra, semaglutide, belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. These medications have been studied for their effects on blood sugar, appetite, and body weight. Making an informed decision about your health is crucial. Consult your healthcare provider before starting any medication.

How Does Poviztra Work?

To understand how Poviztra works, it helps to know about the natural hormone it mimics: GLP-1. This hormone is released in your gut after you eat and plays a key role in managing appetite and blood sugar. Poviztra works by activating the same receptors in the body that GLP-1 does, leading to a few key effects.

Impact on Appetite

GLP-1 receptor agonists like Poviztra target areas of the brain that regulate appetite and food intake. By activating these pathways, the medication can help reduce feelings of hunger and increase feelings of fullness after meals. This can make it easier for individuals to adhere to a lower-calorie diet without feeling constantly deprived.

Slower Digestion

Another key function of this medication is its effect on the digestive system. Poviztra slows down the rate at which your stomach empties its contents after a meal, a process known as gastric emptying. When your stomach empties more slowly, you feel full for a longer period. This extended feeling of satiety can help decrease overall calorie consumption throughout the day.

Who Is Poviztra For?

Poviztra is generally prescribed for adults struggling with chronic weight management. The specific criteria for a prescription are determined by a healthcare provider, but they typically align with guidelines established through clinical studies.

It is often indicated for adults with:

• Obesity, defined as a Body Mass Index (BMI) of 30 kg/m² or greater.
• Overweight, defined as a BMI of 27 kg/m² or greater, who also have at least one weight-related medical condition.

Examples of weight-related health conditions include high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia). A thorough evaluation by a doctor is necessary to determine if Poviztra is a suitable and appropriate option for your individual health situation.

How Is Poviztra Administered?

Poviztra is an injectable medication that is typically administered once a week. It is given as a subcutaneous injection, which means it is injected just under the skin. Common injection sites include the abdomen, the front of the thighs, or the upper arm.

Your healthcare provider or a member of their team will show you how to properly prepare and administer the injection. The pen comes in five strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg). As with Wegovy, the dose usually starts at 0.25 mg once weekly and is increased every 4 weeks, as your doctor decides, towards the 2.4 mg maintenance dose. This dose-escalation schedule is designed to help the body adjust to the medication and minimize potential gastrointestinal side effects.

What Are the Potential Side Effects?

Like all medications, Poviztra comes with a risk of potential side effects. Not everyone will experience them, and they often vary in intensity from person to person. It is important to have an open conversation with your doctor about what to expect.

Common Side Effects

The most frequently reported side effects are related to the gastrointestinal system. These are often most noticeable when starting the medication or after a dose increase and may lessen over time. They can include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain or discomfort
• Indigestion

Serious Side Effects

While less common, serious side effects can occur. It is vital to be aware of the signs and to seek medical attention if you experience them. Your doctor will discuss the full range of potential risks, which may include inflammation of the pancreas (pancreatitis), gallbladder problems, or other conditions noted in the medication's prescribing information.

Less common but serious risks include pancreatitis, gallbladder problems, dehydration that can lead to kidney problems, low blood sugar when semaglutide is used with insulin or a sulfonylurea, and worsening diabetic eye disease (retinopathy) in people with type 2 diabetes. Semaglutide must not be used if you or a family member has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2), and it should not be used in pregnancy. Get urgent medical help for severe stomach pain that does not go away and may spread to your back, signs of a serious allergic reaction such as swelling of the face, lips or throat or trouble breathing, or vomiting or diarrhoea so severe that you cannot keep fluids down. Tell your doctor or anaesthetist that you take semaglutide before any surgery or sedation.

What to Discuss with Your Doctor

A productive conversation with your doctor is the most important step in considering any new treatment. Being prepared for your appointment can help you and your provider make the best decision for your health.

Your Medical History

Be ready to share your complete medical history. This includes any current or past health conditions, particularly if you or any family members have a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). You should also discuss any history of pancreatitis, kidney problems, or gallbladder disease.

Other Medications and Supplements

Provide your doctor with a comprehensive list of everything you take. This includes all prescription medications, over-the-counter drugs, vitamins, and herbal supplements. Some substances can interact with Poviztra, and your doctor needs a full picture to ensure your safety.

Your Goals and Expectations

Talk openly about your weight management goals and what you hope to achieve. This is also a good time to ask questions about the lifestyle changes required for success, the potential results you might see, and how the medication fits into your overall health plan. Remember to consult your healthcare provider before starting any medication.

The Bigger Picture: A Tool, Not a Magic Bullet

It’s essential to view Poviztra as one tool within a larger, more comprehensive weight management strategy. The medication works best when it supports sustainable, long-term lifestyle changes.

Lasting success in weight management is built on a foundation of healthy habits. This includes adopting a nutritious, balanced eating plan, engaging in regular physical activity that you enjoy, and developing healthy behavioral patterns around food and exercise. Support from healthcare teams or comprehensive programs, such as those that help you track progress and stay motivated, can be an important part of the journey. Poviztra can help make these changes more manageable, but it does not replace them.

Sources

• Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra in India (BioSpectrum India, November 10, 2025): https://biospectrumindia.com/news/73/26901/novo-nordisk-india-partners-with-emcure-pharma-to-commercialise-poviztra-in-india.html
• Emcure Pharma launches Poviztra (PTI via The Week, December 22, 2025): https://www.theweek.in/wire-updates/business/2025/12/22/dcm40-biz-emcure-drug-launch.html
• Wegovy (semaglutide) prescribing information (FDA): https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
• MedlinePlus — semaglutide injection: https://medlineplus.gov/druginfo/meds/a618008.html
• Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
• Cleveland Clinic. GLP-1 Agonists. https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
• European Medicines Agency (EMA). (2022). Wegovy (semaglutide) Product Information. https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy